<i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain <i>Ligilactobacillus salivarius</i> PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter,...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/9/9/1933 |
| _version_ | 1797518082709651456 |
|---|---|
| author | Esther Jiménez Susana Manzano Dietmar Schlembach Krzysztof Arciszewski Rocio Martin Kaouther Ben Amor Mieke Roelofs Jan Knol Juan Miguel Rodríguez Michael Abou-Dakn PREMIUM Study Group |
| author_facet | Esther Jiménez Susana Manzano Dietmar Schlembach Krzysztof Arciszewski Rocio Martin Kaouther Ben Amor Mieke Roelofs Jan Knol Juan Miguel Rodríguez Michael Abou-Dakn PREMIUM Study Group |
| author_sort | Esther Jiménez |
| collection | DOAJ |
| description | Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain <i>Ligilactobacillus salivarius</i> PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (<i>p</i> = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; <i>p</i> = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of <i>L. salivarius</i> PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding. |
| first_indexed | 2024-03-10T07:25:11Z |
| format | Article |
| id | doaj.art-7a028226a50845058f5fc33803adad94 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-10T07:25:11Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-7a028226a50845058f5fc33803adad942023-11-22T14:19:19ZengMDPI AGMicroorganisms2076-26072021-09-0199193310.3390/microorganisms9091933<i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled TrialEsther Jiménez0Susana Manzano1Dietmar Schlembach2Krzysztof Arciszewski3Rocio Martin4Kaouther Ben Amor5Mieke Roelofs6Jan Knol7Juan Miguel Rodríguez8Michael Abou-Dakn9PREMIUM Study GroupProbisearch SLU, 28760 Tres Cantos, SpainProbisearch SLU, 28760 Tres Cantos, SpainClinic for Obstetrics, Vivantes Hospital Group, Neukölln, 12351 Berlin, GermanyPoliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. K, 15-435 Białystok, PolandDanone Nutricia Research, 3584 CT Utrecht, The NetherlandsDanone Nutricia Research, 3584 CT Utrecht, The NetherlandsDanone Nutricia Research, 3584 CT Utrecht, The NetherlandsDanone Nutricia Research, 3584 CT Utrecht, The NetherlandsDepartment of Nutrition and Food Science, Complutense University of Madrid, 28040 Madrid, SpainBerlin Center for Diabetes and Pregnancy, Department of Obstetrics and Gynecology, St. Joseph Hospital, 12101 Berlin, GermanyMastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain <i>Ligilactobacillus salivarius</i> PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (<i>p</i> = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; <i>p</i> = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of <i>L. salivarius</i> PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding.https://www.mdpi.com/2076-2607/9/9/1933breastfeeding supportmastitispreventionprobiotics<i>Lactobacillus salivarius</i><i>Ligilactobacillus salivarius</i> |
| spellingShingle | Esther Jiménez Susana Manzano Dietmar Schlembach Krzysztof Arciszewski Rocio Martin Kaouther Ben Amor Mieke Roelofs Jan Knol Juan Miguel Rodríguez Michael Abou-Dakn PREMIUM Study Group <i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial Microorganisms breastfeeding support mastitis prevention probiotics <i>Lactobacillus salivarius</i> <i>Ligilactobacillus salivarius</i> |
| title | <i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
| title_full | <i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
| title_fullStr | <i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
| title_full_unstemmed | <i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
| title_short | <i>Ligilactobacillus salivarius</i> PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
| title_sort | i ligilactobacillus salivarius i ps2 supplementation during pregnancy and lactation prevents mastitis a randomised controlled trial |
| topic | breastfeeding support mastitis prevention probiotics <i>Lactobacillus salivarius</i> <i>Ligilactobacillus salivarius</i> |
| url | https://www.mdpi.com/2076-2607/9/9/1933 |
| work_keys_str_mv | AT estherjimenez iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT susanamanzano iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT dietmarschlembach iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT krzysztofarciszewski iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT rociomartin iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT kaoutherbenamor iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT miekeroelofs iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT janknol iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT juanmiguelrodriguez iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT michaelaboudakn iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT premiumstudygroup iligilactobacillussalivariusips2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial |